News | October 09, 2022
BioMarin simplifies organizational structure to increase efficiency
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
The inspection concluded with no observation (FDA-483) issued.
Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
The company will address the observations within a stipulated timeline working with the regulators
Sildenafil for Oral Suspension (RLD Revatio) had estimated annual sales of US $64 million in the US
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
The companies will leverage their respective proprietary technology platforms
Subscribe To Our Newsletter & Stay Updated
